Epigral Ltd Q4 FY26 Earnings Analysis
Published 17 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹4.8K Cr
Price
₹1,098
Market Cap
₹4.8K Cr
P/E Ratio
17.8
Earnings Summary
The company targets a volume growth of around 10% to 12% for FY27. Epigral targets a volume growth of around 10% to 12% for FY27, driven by capacity expansions in higher value products like CPVC and ECH.
📊 Revenue & Sales Performance
- →The company targets a volume growth of around 10% to 12% for FY27.
- →Revenue growth is expected to improve over FY26, with FY27 anticipated to be better than FY26 in terms of volume and value growth.
- →Capacity additions, especially commissioning of CPVC and Epichlorohydrin (ECH) units, are on track and expected to support growth.
- →Gradual ramp-up to optimum utilization levels by FY28 is planned (CPVC approximately 75%, ECH around 80%).
- →Chlorotoluene product line is expected to contribute sizably in FY27, with volume ramp-up continuing.
- →Despite external uncertainties like war impacts, the company expects steady volume growth unless major disruptions occur.
- →Overall, the company aims for consistent year-on-year momentum and diversification to drive top-line growth.
📈 Profitability & Margins
- →Epigral targets a volume growth of around 10% to 12% for FY27, driven by capacity expansions in higher value products like CPVC and ECH.
- →Value growth is expected to improve alongside volume growth, although the company avoids providing specific revenue or margin guidance.
- →EBITDA margins are expected to be maintained around current levels but no specific margin guidance is provided.
- →Earnings growth may be impacted by factors such as currency volatility, raw material inflation due to geo-political issues (e.g., US-Israel-Iran war), and inflationary pressures.
- →New capacity additions (CPVC and ECH) commissioning in Q2 FY27 and their ramp-up will contribute to earnings growth from FY27 onwards.
- →Longer-term growth is supported by ongoing and future capex projects, with announcements expected in FY27, aimed at sustaining momentum beyond FY29/FY30.
- →Overall, consistent growth in earnings and operating profits is anticipated with cautious optimism amid external risks.
🏗️ Capital Expenditure Plans
- →Epigral is commissioning capacity expansion projects for Epichlorohydrin (ECH) and CPVC in Q2 FY27, expected to ramp up gradually and reach optimum utilization (CPVC ~75%, ECH ~80%) by FY28.
- →They are working on a new greenfield project; site evaluation and due diligence are ongoing with plans to announce the project within the current year to sustain post-FY29 growth.
- →No immediate plans to expand caustic soda capacity, but future capacity increase possible if required.
- →The company follows a cautious, step-by-step capex approach, announcing new projects as existing ones near completion.
- →Significant ongoing capex with around INR 394 crores spent in FY26.
- →Additional wind-solar power capacity (~19.5 MW) is being added to increase renewable energy share to approximately 15%.
💰 Fundraising & Capital Structure
- →The management did not explicitly mention any current or future fundraising through debt or equity during the call.
- →They highlighted ongoing capital expenditure (capex) of INR 394 crores in FY26 and focus on progressing expansion projects (Epichlorohydrin and CPVC) on track and within budget.
- →Net debt increased slightly from INR 489 crores in the previous year to INR 508 crores as of March 31, 2026.
- →Net debt to EBITDA ratio stood at 0.9.
- →Management emphasized disciplined capital deployment aimed at value creation but avoided providing specific guidance on new fundraising.
- →Upcoming capex includes doubling CPVC and ECH capacity, with plans to announce further greenfield projects within the year after due diligence.
- →Overall, no direct indication of raising new debt or equity immediately, though future funding needs could arise aligned with expansion plans.
📋 Order Book & Pipeline
The transcript provided does not explicitly mention the current or expected order book or pending orders for Epigral Limited. However, relevant insights related to demand and volumes include:
- Chlorotoluene had a slow start in FY26 due to approvals/testing; significant volume pickup expected in FY27 with utilization around 40%.
- Demand is expected to improve gradually from May onwards after some recent uncertainties due to global geopolitical tensions.
- There is a volume growth expectation of around 10-12% in FY27, driven by normalizing demand conditions and capacity expansions.
- Ramp-up of new capacities for CPVC and ECH slated to begin in Q2 FY27, reaching optimal utilization by FY28.
- The company is cautiously managing orders and inventory amid price volatility in raw materials and derivatives.
For specific current or pending order book numbers, no concrete data is disclosed in the available transcript.
Key Metrics
Frequently Asked Questions
What were Epigral Ltd Q4 FY26 results?
The company targets a volume growth of around 10% to 12% for FY27. Epigral targets a volume growth of around 10% to 12% for FY27, driven by capacity expansions in higher value products like CPVC and ECH.
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Epigral is commissioning capacity expansion projects for Epichlorohydrin (ECH) and CPVC in Q2 FY27, expected to ramp up gradually and reach optimum utilization (CPVC ~75%, ECH ~80%) by FY28.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.